Group v secretory phospholipase A 2 Enhances the progression of angiotensin IIInduced abdominal aortic aneurysms but confers protection against angiotensin iiinduced cardiac fibrosis in ApoE-deficient mice

American Journal of Pathology

Volumn 181, Issue 3, 2012, Pages 1088-1098

  Boyanovsky, Boris B ^a   Bailey, William ^a   Dixon, Lauren ^b   Shridas, Preetha ^a   Webb, Nancy R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b KENTUCKY STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; APOLIPOPROTEIN E; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SECRETORY PHOSPHOLIPASE A2;

ABDOMINAL AORTA ANEURYSM; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; DISEASE COURSE; ENZYME INDUCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERIVASCULAR FIBROSIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS;

ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; APOLIPOPROTEINS E; APOPTOSIS; COLLAGEN; DISEASE PROGRESSION; FIBROSIS; GROUP V PHOSPHOLIPASES A2; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NADPH OXIDASE; PROSTAGLANDINS;

EID: 84865272103     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.05.037     Document Type: Article

References (56)

1. S. Ueda New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: questions remain unsolved J Pharm Sci 113 2010 292 295
2. P.K. Mehta, K.K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol 292 2007 C82 C97
3. C. Marchesi, P. Paradis, E.L. Schiffrin Role of the reninangiotensin system in vascular inflammation Trends Pharmacol Sci 29 2008 367 374
4. R.V. Shah, A.S. Desai, M.M. Givertz The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis J Card Fail 16 2010 260 267
5. H. Yoshida, M. Takahashi, K. Tanonaka, T. Maki, Y. Nasa, S. Takeo Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure Br J Pharmacol 134 2001 150 160
6. R.M. Touyz Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology Antioxid Redox Signal 7 2005 1302 1314
7. M. Zack, B.B. Boyanovsky, P. Shridas, W. Bailey, K. Forrest, D.A. Howatt, M.H. Gelb, F.C. de Beer, A. Daugherty, N.R. Webb Group X secretory phospholipase A2 augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice Atherosclerosis 214 2011 58 64
8. N. Sakalihasan, R. Limet, O.D. Defawe Abdominal aortic aneurysm Lancet 365 2005 1577 1589
9. A. Daugherty, L.A. Cassis Mouse models of abdominal aortic aneurysms Arterioscler Thromb Vasc Biol 24 2004 429 434
10. G. Lambeau, M.H. Gelb Biochemistry and physiology of mammalian secreted phospholipases A2 Annu Rev Biochem 77 2008 495 520
11. B.B. Boyanovsky, N.R. Webb Biology of secretory phospholipase A2 Cardiovasc Drugs Ther 23 2009 61 72
12. B. Ivandic, L.W. Castellani, X.-P. Wang, J.-H. Qiao, M. Mehrabian, M. Navab, A.M. Fogelman, D.S. Grass, M.E. Swanson, M.C. de Beer, F. de Beer, A.J. Lusis Role of group II secretory phospholipase A2 in atherosclerosis: increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa secretory phospholipase A2 Arterioscler Thromb Vasc Biol 19 1999 1284 1290
13. M.A. Bostrom, B.B. Boyanovsky, C.T. Jordan, M.P. Wadsworth, D.J. Taatjes, F.C. de Beer, N.R. Webb Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice Arterioscler Thromb Vasc Biol 27 2007 600 606
14. M.M. Taketo, M. Sonoshita Phospolipase A2 and apoptosis Biochim Biophys Acta 1585 2002 72 76
15. S. Giri, M. Khan, R. Rattan, I. Singh, A.K. Singh Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death J Lipid Res 47 2006 1478 1492
16. X. Zhao, D. Wang, Z. Zhao, Y. Xiao, S. Sengupta, Y. Xiao, R. Zhang, K. Lauber, S. Wesselborg, L. Feng, T.M. Rose, Y. Shen, J. Zhang, G. Prestwich, Y. Xu Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells J Biol Chem 281 2006 29357 29368
17. R. Muralikrishna Adibhatla, J.F. Hatcher Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia Free Radic Biol Med 40 2006 376 387
18. T. Matsusaka, H. Katori, T. Homma, I. Ichikawa Mechanism of cardiac fibrosis by angiotensin: new insight revealed by genetic engineering Trends Cardiovasc Med 9 1999 180 184
19. Y. Satake, B.L. Diaz, B. Balestrieri, B.K. Lam, Y. Kanaoka, M.J. Grusby, J.P. Arm Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption J Biol Chem 279 2004 16488 16494
20. A. Daugherty, L. Cassis Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice Ann N Y Acad Sci 892 1999 108 118
21. A. Daugherty, M.W. Manning, L.A. Cassis Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis Br J Pharmacol 134 2001 865 870
22. M. Wadsworth, B. Sobel, D. Schneider, D. Taatjes Delineation of the evolution of compositional changes in atheroma Histochem Cell Biol 118 2002 59 68
23. W. Su, O. Yeku, S. Olepu, A. Genna, J.-S. Park, H. Ren, G. Du, M.H. Gelb, A.J. Morris, M.A. Frohman 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis Mol Pharmacol 75 2009 437 446
24. K. Saraff, F. Babamusta, L.A. Cassis, A. Daugherty Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 23 2003 1621 1626
25. J. Balsinde, M. Balboa, E. Dennis Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2 Proc Natl Acad Sci U S A 95 1998 7951 7956
26. H. Shinohara, M.A. Balboa, C.A. Johnson, J. Balsinde, E.A. Dennis Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s J Biol Chem 274 1999 12263 12268
27. L. Cupillard, K. Koumanov, M.-G. Mattei, M. Lazdunski, G. Lambeau Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2 J Biol Chem 272 1997 15745 15752
28. E. Valentin, F. Ghomashchi, M. Gelb, M. Lazdunski, G. Lambeau On the diversity of secreted phospholipases A2 J Biol Chem 274 1999 31195 31202
29. T. Yano, D. Fujioka, Y. Saito, T. Kobayashi, T. Nakamura, J.E. Obata, K. Kawabata, K. Watanabe, Y. Watanabe, H. Mishina, S. Tamaru, K. Kugiyama Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury Cardiovasc Res 90 2011 335 343
30. Y. Ishikawa, K. Komiyama, S. Masuda, M. Murakami, Y. Akasaka, K. Ito, Y. Akishima-Fukasawa, M. Kimura, A. Fujimoto, I. Kudo, T. Ishii Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction Histopathology 47 2005 257 267
31. C.M. Werner, M. Bhm Review: the therapeutic role of RAS blockade in chronic heart failure Ther Adv Cardiovasc Dis 2 2008 167 177
32. K.K. Griendling, D. Sorescu, M. Ushio-Fukai NAD(P)H oxidase: role in cardiovascular biology and disease Circ Res 86 2000 494 501
33. A. Nabeebaccus, M. Zhang, A. Shah NADPH oxidases and cardiac remodelling Heart Fail Rev 16 2011 5 12
34. S.D. Hingtgen, X. Tian, J. Yang, S.M. Dunlay, A.S. Peek, Y. Wu, R.V. Sharma, J.F. Engelhardt, R.L. Davisson Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy Physiol Genomics 26 2006 180 191
35. A.C. Cave, A.C. Brewer, A. Narayanapanicker, R. Ray, D.J. Grieve, S. Walker, A.M. Shah NADPH oxidases in cardiovascular health and disease Antioxid Redox Signal 8 2006 691 728
36. J.K. Bendall, A.C. Cave, C. Heymes, N. Gall, A.M. Shah Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice Circulation 105 2002 293 296
37. C. Murdoch, S. Alom-Ruiz, M. Wang, M. Zhang, S. Walker, B. Yu, A. Brewer, A. Shah Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction Basic Res Cardiol 106 2011 527 538
38. J. Kuroda, T. Ago, S. Matsushima, P. Zhai, M.D. Schneider, J. Sadoshima NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart Proc Natl Acad Sci U S A 107 2010 15565 15570
39. H. Fraser, C. Hislop, R.M. Christie, H.L. Rick, C.A. Reidy, M.L. Chouinard, P.I. Eacho, K.E. Gould, J. Trias Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice J Cardiovasc Pharmacol 53 2009 60 65
40. R.S. Rosenson Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes Curr Opin Lipidol 21 2010 473 480
41. B.C. Tieu, C. Lee, H. Sun, W. LeJeune, A. Recinos, X. Ju, H. Spratt, D.-C. Guo, D. Milewicz, R.G. Tilton, A.R. Brasier An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice J Clin Invest 119 2009 3637 3651
42. J. Golledge, Z. Mallat, A. Tedgui, P.E. Norman Serum secreted phospholipase A2 is associated with abdominal aortic aneurysm presence but not progression Atherosclerosis 216 2011 458 460
43. T.J. Nevalainen, L.I. Eerola, E. Rintala, V.J.O. Laine, G. Lambeau, M.H. Gelb Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum Biochim Biophys Acta 1733 2005 210 223
44. A. Leask Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation Circ Res 106 2010 1675 1680
45. J.P. van Kats, D. Methot, P. Paradis, D.W. Silversides, T.L. Reudelhuber Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice J Biol Chem 276 2001 44012 44017
46. J. Xu, O.A. Carretero, T.-D. Liao, H. Peng, E.G. Shesely, J. Xu, T.S. Liu, J.J. Yang, T.L. Reudelhuber, X.-P. Yang Local angiotensin II aggravates cardiac remodeling in hypertension Am J Physiol 299 2010 H1328 H1338
47. S. Billet, S. Bardin, S. Verp, V. Baudrie, A. Michaud, S. Conchon, M. Muffat-Joly, B. Escoubet, E. Souil, G. Hamard, K.E. Bernstein, J.M. Gasc, J.-L. Elghozi, P. Corvol, E. Clauser Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice J Clin Invest 117 2007 1914 1925
48. J. Chen, S.J. Engle, J.J. Seilhamer, J.A. Tischfield Cloning and recombinant expression of a novel human low molecular weight Ca(2+)-dependent phospholipase A2 J Biol Chem 269 1994 2365 2368
49. M. Murakami, S. Shimbara, T. Kambe, H. Kuwata, M.V. Winstead, J.A. Tischfield, I. Kudo The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release: type IIa and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A2 J Biol Chem 273 1998 14411 14423
50. B.L. Diaz, Y. Satake, E. Kikawada, B. Balestrieri, J.P. Arm Group V secretory phospholipase A2 amplifies the induction of cyclooxygenase 2 and delayed prostaglandin D2 generation in mouse bone marrow culture-derived mast cells in a strain-dependent manner Biochim Biophys Acta 1761 2006 1489 1497
51. J. Balsinde, H. Shinohara, L.J. Lefkowitz, C.A. Johnson, M.A. Balboa, E.A. Dennis Group V phospholipase A(2)-dependent induction of cyclooxygenase-2 in macrophages J Biol Chem 274 1999 25967 25970
52. D. Wang, V.V. Patel, E. Ricciotti, R. Zhou, M.D. Levin, E. Gao, Z. Yu, V.A. Ferrari, M.M. Lu, J. Xu, H. Zhang, Y. Hui, Y. Cheng, N. Petrenko, Y. Yu, G.A. FitzGerald Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function Proc Natl Acad Sci U S A 106 2009 7548 7552
53. J.M. Gitlin, C.D. Loftin Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice Cardiovasc Res 81 2009 400 407
54. E. Ricciotti, G.A. FitzGerald Prostaglandins and inflammation Arterioscler Thromb Vasc Biol 31 2011 986 1000
55. V.L. King, D.B. Trivedi, J.M. Gitlin, C.D. Loftin Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice Arterioscler Thromb Vasc Biol 26 2006 1137 1143
56. B. Balestrieri, V.W. Hsu, H. Gilbert, C.C. Leslie, W.K. Han, J.V. Bonventre, J.P. Arm Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis J Biol Chem 281 2006 6691 6698